Melbourne scientists have revealed a better way to identify which patients should respond to powerful ovarian cancer drugs called PARP inhibitors (PARPi), resolving an important question in ovarian cancer care about why some patients respond to the drugs, while others do not.
The findings add to a vital ‘checklist’ that helps match ovarian cancer patients with the right therapy for their cancer. Being able to offer targeted treatment is crucial for patient survival rates which have seen little improvement over the past 30 years.
The study, published in Nature Communications, was led by Professor Clare Scott, Dr Olga Kondrashova, Dr Matthew Wakefield and Dr Monique Topp from the Walter and Eliza Hall Institute; in collaboration with Associate Professor Alexander Dobrovic from the Olivia Newton-John Cancer Research Institute and LaTrobe University School of Medicine.
Subtle yet significant differences
Professor Scott said it was well documented that PARPi could only work when the cancer’s DNA repair process wasn’t functioning as it should.
Read more at Walter and Eliza Hall Institute
Image: New ovarian cancer research reveals how to better match patients with the right treatment. (L-R) Dr Olga Kondrashova and Professor Clare Scott led the research. (Credit: Walter and Eliza Hall Institute)